Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI321 in Advanced Solid Tumors
NCT05172856Phase 1Unknown
- Sponsor
- Innovent Biologics
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI321 in solid tumor (advanced stage), sponsored by Innovent Biologics. Primary endpoint: Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
IBI321
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05172856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172856.